Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial

Fig. 5

Secondary exercise capacity endpoints. a Total exercise time ETT-1 placebo vs. ETT-3 1.2 mg liraglutide. b Total exercise time ETT-2 placebo vs. ETT-4 1.8 mg liraglutide. c Recovery time to 0.05 mV ST-segment depression ETT-1 placebo vs. ETT-3 1.2 mg liraglutide. d Recovery time to 0.05 mV ST-segment depression ETT-2 placebo vs. ETT-4 1.8 mg liraglutide

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us